Repurposing cytarabine for treating primary effusion lymphoma by targeting KSHV latent and lytic replications
M. Gruffaz, S. Zhou, K. Vasan, T. Rushing, Q. L. Michael, C. Lu, J. U. Jung, S.-J. Gao
This study identifies cytarabine as a potent inhibitor of KSHV-induced primary effusion lymphoma by targeting both viral and host DNA/RNA synthesis and inducing tumor regression in a xenograft model.
bioRxiv · Apr 11, 2018Microbiology